Lindsey Shapiro, PhD,  science writer—

An interactive electronic storybook, or e-book, designed to help children with atypical hemolytic uremic syndrome (aHUS) better understand their rare disease, has been launched by Alexion, AstraZeneca Rare Disease, which markets two aHUS therapies. Called “Revealing the Secrets of aHUS,” the fantasy e-book uses imaginative play to…

It may be safe for some adults with atypical hemolytic uremic syndrome (aHUS) to discontinue treatment once they’re clinically stable, but a decision depends on a complex group of factors, a study based on interviews with aHUS experts indicates. The patient’s health status, personal preferences, and access to close…

The National Organization for Rare Disorders (NORD) is offering patient assistance programs specifically for people in the U.S. with atypical hemolytic uremic syndrome (aHUS), to help cover out-of-pocket medical costs and emergency nonmedical expenses in their daily lives. These initiatives come under NORD’s RareCare program, which was…

Long-term treatment with Ultomiris (ravulizumab) led to sustained clinical improvements for adults and children with atypical hemolytic uremic syndrome (aHUS), according to new two-year data from a pair of clinical trials. Patients in both age groups saw improvements in blood-related health factors and kidney function, and experienced less…

Treatment with Soliris (eculizumab) helped about half of the children diagnosed with atypical hemolytic uremic syndrome (aHUS) after they received a stem cell transplant, according to a small study. Among 13 patients who started taking Soliris, seven survived and saw their disease-associated biomarkers normalize. Six died due to complications…

Blood concentrations of Soliris (eculizumab) needed to fully suppress the immune complement cascade may be higher than previously thought in people with atypical hemolytic uremic syndrome (aHUS), according to a study from Spain. Most patients were found to have concentrations above estimated therapeutic levels in their bloodstream before…

Relapses were less likely in people with atypical hemolytic uremic syndrome (aHUS) treated with Soliris (eculizumab) after a kidney transplant, and they had better kidney function and a lower risk of transplant rejection, according to a meta-analysis of published studies. “This meta-analysis … demonstrated that [Soliris] produced meaningful…

People with atypical hemolytic uremic syndrome (aHUS) have an immune cell profile distinct from that of healthy people and unaffected family members, a recent study reported. Its scientists identified a range of immune cell types, genes, and signaling pathways that could ultimately serve as disease biomarkers — with the…

Vaccination against COVID-19 was linked to the onset or recurrence of atypical hemolytic uremic syndrome (aHUS) in three Dutch patients in a recent case report. Researchers didn’t find any additional cases wherein a vaccination could be tied to aHUS relapse in a retrospective analysis of 41 other aHUS patients…

Two infants developed atypical hemolytic uremic syndrome (aHUS) caused by mutations in the EXOSC3 gene and subsequent COVID-19 infections, as described in a recent case report. The cases, which are unusual in that they do not involve an imbalance of the immune system’s complement pathway, may offer insights into new…